Positive outcomes for Lenti-D trial, bluebird chasing regulatory approvals
Bluebird bio has reported end points were met in a clinical trial involving its candidate ALD cell therapy, branded as Lenti-D.
Archives for September 3, 2020
Mylan, Biocon target Sanofi with deeply discounted Lantus copycat
Mylan and Biocon price copy of Sanofi’s Lantus at 65% discount, setting up a fight for the blockbuster diabetes opportunity.
House committee set to subpoena AbbVie over Humira pricing
The House Committee on Oversight and Reform plans to subpoena AbbVie over pricing of Humira and Imbruvica, alleging the company repeatedly failed to comply with requests.
Analysts tip COVID-19 vaccines to generate $40bn next year
Morningstar analysts tip a handful of COVID-19 vaccine developers to share a $40 billion market next year.
Sanofi and GSK start Phase 1/2 clinical trial of COVID-19 vaccine candidate
Sanofi and GSK today start the Phase 1/2 clinical trial for their COVID-19 adjuvanted recombinant protein-based vaccine candidate.